



NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES

Vodis Announces Name Change

Vancouver, British Columbia, December 3, 2020 - Vodis Pharmaceuticals Inc. (CSE: VP, FSE: 1JV1, OTC: VDQSF) (“Vodis” or the “Company”) is pleased to announce that it has changed its name from Vodis Pharmaceuticals Inc. to Gnomestar Craft Inc. and its ticker symbol from “VP” to “GNOM”. Subject to approval of the Canadian Securities Exchange (the “CSE”), the Company expects the name and symbol change to take effect on December 7, 2020 when its common shares will begin trading on the CSE under the new name “Gnomestar Craft Inc.” and new ticker symbol “GNOM”.

No action is required by existing shareholders with respect to the name and ticker symbol change. Certificates representing common shares of Vodis Pharmaceuticals Inc. will not need to be exchanged as a result of the name change.

For further information please contact:

Mark Lotz, Chief Executive Officer
Vodis Pharmaceuticals Inc.
Email: mark@vodis.ca

Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Forward-Looking Information: *This news release contains “forward-looking information” within the meaning of applicable securities laws including statements relating to the outlook of the business of the Company, the planned expenditures for upgrades and other renovations at the Company’s facilities in Delta, BC. Although the Company believes considering the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them as the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements, depending on, among other things, the risks that the private placement financings may not close for any reason (including the failure to obtain the required approvals or clearances from regulatory authorities) or that the terms of the private placement financing may differ from those that currently are contemplated. The statements in this news release are made as of the date of this release. The Company is under no obligation, and*

expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.